Perinatal acquisition of drug-resistant HIV-1 infection: Mechanisms and long-term outcome

Retrovirology

Volumn 6, Issue , 2009, Pages 85-

  Delaugerre, Constance ^a,b   Chaix, Marie Laure ^a,b   Blanche, Stephane ^b   Warszawski, Josiane ^c   Cornet, Dorine ^b   Dollfus, Catherine ^d   Schneider, Veronique ^e   Burgard, Marianne ^b   Faye, Albert ^f   Mandelbrot, Laurent ^g   Tubiana, Roland ^h   Rouzioux, Christine ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g HÔPITAL LOUIS MOURIER   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFECTION PREVENTION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MOTHER; NEWBORN; NONHUMAN; PERINATAL PERIOD; PHYLOGENY; VERTICAL TRANSMISSION; VIRUS STRAIN; WILD TYPE;

ANTIVIRAL AGENTS; CHEMOPREVENTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGNOSIS; RNA, VIRAL; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70449364797     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-85     Document Type: Article

References (36)

1. Rouzioux C, Costagliola D, Burgard M, Blanche S, Mayaux MJ, Griscelli C, Valleron AJ. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995, 142:1330-1337.
2. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180. 10.1056/NEJM199411033311801, 7935654.
3. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002, 29:484-494.
4. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, Faye A, Burgard M, Rouzioux C, Mandelbrot L. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. Aids 2008, 22:289-299. 10.1097/QAD.0b013e3282f3d63c, 18097232.
5. Yeni P. Prise en charge meìdicale des personnes infecteìes par le VIH Flammarion edn 2008, Paris: Médecine-Sciences.
6. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001, 183:1688-1693. 10.1086/320697, 11343221.
7. Masquelier B, Chaix ML, Burgard M, Lechenadec J, Doussin A, Simon F, Cottalorda J, Izopet J, Tamalet C, Douard D. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 2001, 27:99-104.
8. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet 1994, 344:1771-1772. 10.1016/S0140-6736(94)92911-4, 7997023.
9. Fiscus SA, Adimora AA, Schoenbach VJ, Lim W, McKinney R, Rupar D, Kenny J, Woods C, Wilfert C. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. Jama 1996, 275:1483-1488. 10.1001/jama.275.19.1483, 8622222.
10. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004, 350:2471-2480. 10.1056/NEJMoa032706, 15190139.
11. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr 2002, 30:216-229.
12. Palumbo P, Holland B, Dobbs T, Pau CP, Luo CC, Abrams EJ, Nesheim S, Vink P, Respess R, Bulterys M. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001, 184:1120-1126. 10.1086/323804, 11598834.
13. Parker MM, Wade N, Lloyd RM, Birkhead GS, Gallagher BK, Cheku B, Sullivan T, Taylor J. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr 2003, 32:292-297. 10.1097/00126334-200303010-00008, 12626889.
14. Karchava M, Pulver W, Smith L, Philpott S, Sullivan TJ, Wethers J, Parker MM. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr 2006, 42:614-619. 10.1097/01.qai.0000225871.87456.e7, 16868498.
15. Mayaux MJ, Teglas JP, Mandelbrot L, Berrebi A, Gallais H, Matheron S, Ciraru-Vigneron N, Parnet-Mathieu F, Bongain A, Rouzioux C. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr 1997, 131:857-862. 10.1016/S0022-3476(97)70033-7, 9427890.
16. Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, Chaix ML, Calvez V, Brun-Vezinet F, Costagliola D. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006, 78:153-160. 10.1002/jmv.20522, 16372300.
17. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro J, Richman DD. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008, 16:62-68.
18. Felsenstein J. The troubled growth of statistical phylogenetics. Syst Biol 2001, 50:465-467. 10.1080/10635150119297, 12116645.
19. Avettand-Fenoel V, Chaix ML, Blanche S, Burgard M, Floch C, Kadidia T, Allemon MC, Warszawski J, Rouzioux C. LTR Real-time PCR for HIV-1 DNA Quantitation in Blood Cells for Early Diagnosis in Infants born to Seropositive Mothers in HAART area (ANRS CO 01). J Med Virol 2009, 81:217-23. 10.1002/jmv.21390, 19107966.
20. Juethner SN, Williamson C, Ristig MB, Tebas P, Seyfried W, Aberg JA. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr 2003, 32:153-156.
21. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, Firtion G, Pons G, Mandelbrot L. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004, 48:4332-4336. 10.1128/AAC.48.11.4332-4336.2004, 525408, 15504861.
22. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). Aids 1999, 13:479-486. 10.1097/00002030-199903110-00006, 10197376.
23. Newstein M, Losikoff P, Caliendo A, Ingersoll J, Kurpewski J, Hanley D, Cerezo J, Ramratnam B, Cu-Uvin S. Prevalence and persistence of nonnucleoside reverse transcriptase inhibitor mutations in the female genital tract. J Acquir Immune Defic Syndr 2005, 38:364-366.
24. Persaud D, Palumbo P, Ziemniak C, Chen J, Ray SC, Hughes M, Havens P, Purswani M, Gaur AH, Chadwick EG. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007, 195:1402-1410. 10.1086/513871, 17436219.
25. Chaix ML, Ekouevi DK, Peytavin G, Rouet F, Tonwe-Gold B, Viho I, Bequet L, Amani-Bosse C, Menan H, Leroy V. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother 2007, 51:896-901. 10.1128/AAC.00910-06, 1803117, 17178792.
26. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005, 192:24-29. 10.1086/430742, 15942890.
27. Giuliano M, Galluzo C, Germinario E, Amici R, Bassani L, Deho L, Vyankandondera J, Mmiro F, Okong P, Vella S. Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV. J Acquir Immune Defic Syndr 2006, 42:131-133. 10.1097/01.qai.0000209911.10071.18, 16763503.
28. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002, 76:1753-1761. 10.1128/JVI.76.4.1753-1761.2002, 135882, 11799170.
29. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, Krivine A, Compagnucci A, Katlama C, Girard PM, Calvez V. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004, 9:415-421.
30. Delaugerre C, Marcelin AG, Soulie C, Chaix ML, Katlama C, Girard PM, Calvez V, Morand-Joubert L. Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey. Aids 2007, 21:1365-1367. 10.1097/QAD.0b013e3280d6edf1, 17545716.
31. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. Aids 2006, 20:159-170. 10.1097/01.aids.0000199820.47703.a0, 16511408.
32. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008, 82:5510-5518. 10.1128/JVI.02579-07, 2395184, 18353964.
33. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, Tubiana R, Simon A, Bricaire F, Agut H. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. Aids 2001, 15:2189-2191. 10.1097/00002030-200111090-00016, 11684940.
34. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007, 356:135-147. 10.1056/NEJMoa062876, 17215531.
35. Welles SL, Bauer GR, LaRussa PS, Colgrove RC, Pitt J. Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr 2007, 44:329-335. 10.1097/QAI.0b013e31802f1296, 17179768.
36. Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmuck A, Schneider V, Tamalet C. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 2007, 12:1305-1310.